BiotechTube
Luna Diabetes

Luna Diabetes

San Francisco, United States· Est.
lunadiabetes.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Luna Diabetes is a private, pre-revenue digital health startup founded in 2019 by industry veterans with deep personal and professional experience in diabetes care. The company is developing 'Luna,' an investigational automated insulin delivery device that attaches to standard insulin pens to provide overnight glycemic control for users on multiple daily injection (MDI) therapy, a significant and underserved market segment. By focusing exclusively on nighttime automation, Luna seeks to offer a simpler, more accessible alternative to traditional insulin pumps, potentially improving outcomes for millions of patients. The company is currently in the development and testing phase, gathering clinical validation and preparing for regulatory submission and commercial launch.

MetabolicDiabetes

Technology Platform

A wearable device that attaches to standard insulin pens, integrating with continuous glucose monitors (CGM) to deliver automated micro-boluses of insulin overnight via a proprietary control algorithm. Designed for simplicity with one-time basal dose setup.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

Luna targets the massive, underserved market of insulin pen users (over 90% of insulin-dependent patients) who seek better overnight glucose control without switching to a traditional pump.
The device's simplicity and 'untethered' daytime design could drive high adoption, creating a new product category in automated insulin delivery.

Risk Factors

Key risks include regulatory hurdles in obtaining FDA clearance for an automated dosing device, the need for robust clinical data proving safety and efficacy, and potential competition from established pump companies or new entrants.
Market adoption depends on convincing patients, doctors, and payers of the value proposition.

Competitive Landscape

Luna operates in a niche between traditional insulin pumps (e.g., from Medtronic, Tandem, Insulet) and smart pen caps/connected pens (e.g., Novo Nordisk's connected pens, Companion Medical's InPen). Its primary competition is the status quo (MDI without automation), but it may face future competition from companies developing simpler, cheaper pump alternatives or other overnight automation solutions for pen users.

More companies in Drug Delivery & Formulation →More companies in United States →